Feigh M - Search Results

1

Increased hepatoprotective effects of the novel farnesoid X receptor agonist INT-787 versus obeticholic acid in a mouse model of nonalcoholic steatohepatitis.

Adorini L, Rigbolt K, Feigh M, Roth J, Erickson M. Adorini L, et al. Among authors: feigh m. PLoS One. 2024 Apr 25;19(4):e0300809. doi: 10.1371/journal.pone.0300809. eCollection 2024. PLoS One. 2024. PMID: 38662778 Free PMC article.

2

Dietary intervention reverses molecular markers of hepatocellular senescence in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.

Flensted-Jensen M, Oró D, Rørbeck EA, Zhang C, Madsen MR, Madsen AN, Norlin J, Feigh M, Larsen S, Hansen HH. Flensted-Jensen M, et al. Among authors: feigh m. BMC Gastroenterol. 2024 Feb 2;24(1):59. doi: 10.1186/s12876-024-03141-x. BMC Gastroenterol. 2024. PMID: 38308212 Free PMC article.

3

Semaglutide reduces tumor burden in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH-HCC with advanced fibrosis.

Hansen HH, Pors S, Andersen MW, Vyberg M, Nøhr-Meldgaard J, Nielsen MH, Oró D, Madsen MR, Lewinska M, Møllerhøj MB, Madsen AN, Feigh M. Hansen HH, et al. Among authors: feigh m. Sci Rep. 2023 Dec 27;13(1):23056. doi: 10.1038/s41598-023-50328-5. Sci Rep. 2023. PMID: 38155202 Free PMC article.

4

Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.

Monfeuga T, Norlin J, Bugge A, Gaalsgaard ED, Prada-Medina CA, Latta M, Veidal SS, Petersen PS, Feigh M, Holst D. Monfeuga T, et al. Among authors: feigh m. Mol Metab. 2024 Jan;79:101850. doi: 10.1016/j.molmet.2023.101850. Epub 2023 Dec 7. Mol Metab. 2024. PMID: 38065435 Free PMC article.

5

Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis.

Nielsen MH, Gillum MP, Vrang N, Jelsing J, Hansen HH, Feigh M, Oró D. Nielsen MH, et al. Among authors: feigh m. Am J Physiol Gastrointest Liver Physiol. 2023 May 1;324(5):G378-G388. doi: 10.1152/ajpgi.00157.2022. Epub 2023 Feb 28. Am J Physiol Gastrointest Liver Physiol. 2023. PMID: 36852934 Free article.

6

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease.

Secor JD, Cho BS, Yu LJ, Pan A, Ko VH, Dao DT, Feigh M, Anez-Bustillos L, Fell GL, Fraser DA, Gura KM, Puder M. Secor JD, et al. Among authors: feigh m. Lipids. 2022 Jul;57(4-5):241-255. doi: 10.1002/lipd.12351. Epub 2022 Jul 1. Lipids. 2022. PMID: 35778847 Free PMC article.

7

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis.

Nestor JJ, Parkes D, Feigh M, Suschak JJ, Harris MS. Nestor JJ, et al. Among authors: feigh m. Sci Rep. 2022 Apr 23;12(1):6666. doi: 10.1038/s41598-022-10577-2. Sci Rep. 2022. PMID: 35461369 Free PMC article.

8

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH.

Møllerhøj MB, Veidal SS, Thrane KT, Oró D, Overgaard A, Salinas CG, Madsen MR, Pfisterer L, Vyberg M, Simon E, Broermann A, Vrang N, Jelsing J, Feigh M, Hansen HH. Møllerhøj MB, et al. Among authors: feigh m. Clin Transl Sci. 2022 May;15(5):1167-1186. doi: 10.1111/cts.13235. Epub 2022 Feb 24. Clin Transl Sci. 2022. PMID: 35143711 Free PMC article.

9

Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.

Perakakis N, Chrysafi P, Feigh M, Veidal SS, Mantzoros CS. Perakakis N, et al. Among authors: feigh m. Int J Mol Sci. 2021 Jun 13;22(12):6332. doi: 10.3390/ijms22126332. Int J Mol Sci. 2021. PMID: 34199317 Free PMC article.

10

Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non-alcoholic steatohepatitis.

Perakakis N, Stefanakis K, Feigh M, Veidal SS, Mantzoros CS. Perakakis N, et al. Among authors: feigh m. Liver Int. 2021 Aug;41(8):1853-1866. doi: 10.1111/liv.14888. Epub 2021 Apr 21. Liver Int. 2021. PMID: 33788377

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page